Single, on-demand treatment with the investigational oral medicine KVD900 safely and significantly slowed the progression of swelling attacks and…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
KVD900, an oral experimental on-demand treatment for swelling episodes caused by hereditary angioedema (HAE), safely and significantly reduced…
The U.S. Food and Drug Administration (FDA) has placed a hold on KalVista Pharmaceuticals’…
Off-label C1 inhibitor concentrate successfully treated people with severe acute angioedema triggered by…
The vast majority of people with hereditary angioedema (HAE) stress the importance of…
PHA121 (PHA-022121), Pharvaris‘ oral therapy for hereditary angioedema (HAE), outperformed Firazyr (icatibant…
Regular Haegarda treatment in older people with hereditary angioedema (HAE) — those…